Trial reportCancer immunology, immunotherapy : CII2008
Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.
Trial report in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Identification and analysis of prognostic ion homeostasis characteristics in kidney renal clear cell carcinoma.Heliyon · 2025Article
- Downregulation of FXYD2 Is Associated with Poor Prognosis and Increased Regulatory T Cell Infiltration in Clear Cell Renal Cell Carcinoma.Journal of immunology research · 2022Article
- Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.Human gene therapy · 2015Review
- Suppression, subversion and escape: the role of regulatory T cells in cancer progression.Clinical and experimental immunology · 2013Review
- Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.Cancer immunology, immunotherapy : CII · 2012Article
- The long road to immunotherapy for childhood rhabdomyosarcoma.Pediatric blood & cancer · 2011Article
- Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.Pediatric blood & cancer · 2011Article
- Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.Cancers · 2011Article
- Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2010Article
- Redirecting the immune response: role of adoptive T cell therapy.Human gene therapy · 2010Review
- Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).Cancer immunology, immunotherapy : CII · 2009Article
- Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.Current molecular medicine · 2009Review
- Cellular immunotherapy for ovarian cancer.Expert opinion on biological therapy · 2009Review
- Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.Journal of molecular medicine (Berlin, Germany) · 2009Review
- CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells.Cancer immunology, immunotherapy : CII · 2008Article
- Cyclophosphamide enhances the immunosuppressive action of its own active metabolites.Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sectionsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCD4(+)CD25(+) regulatory T (T(reg)) cells are present in increased numbers in patients with advanced cancer and CD25(+) T cell depletion potentiates tumour immunity in animal models. The aim of this study was to assess the feasibility and safety of adoptive transfer of CD25(+) depleted autologous T cells in patients with advanced renal cell carcinoma and to examine resulting changes in lymphocyte subsets. PATIENTS AND
methodsSix patients with advanced renal cell carcinoma underwent leukapheresis followed by conditioning chemotherapy with cyclophosphamide and fludarabine. The autologous leukapheresis product was depleted of CD25(+) cells using CliniMACS System then re-infused into the patient.
resultsEfficient CD25(+) depletion from all leukapheresis products was achieved and 0.55-5.87 x 10(7)/kg CD3(+) cells were re-infused. Chemotherapy related haematological toxicity was observed, but blood counts recovered in all patients allowing discharge after a mean inpatient stay of 21 days. One patient subsequently developed a rapidly progressive neurological syndrome. A transient reduction in CD25(+) subset was noted in the peripheral blood of 5 out of 6 patients with evidence of increased T cell responses to PHA in 4 out of 6 patients. One patient showed increased specific proliferative responses to the tumour associated antigen h5T4 coinciding with the nadir of T(reg) cells.
conclusionsGiven the transient nature of the reduction in CD25(+) subset and the observed toxicity there is a need to explore further strategies to improve the safety and efficacy of this approach. Nevertheless, the results provide proof of concept in potentiation of tumour antigen T cell responses when T(reg) cell levels are depleted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.